METHODS OF GENE THERAPY FOR TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA
Abstract
Inherited epidermolysis bullosa (EB) is a heterogeneous group of rare genodermatoses with a high skin fragility manifested by the formation of destructive blisters and non-healing erosions on the skin and mucous membranes as a reaction to minor mechanical influences. There are three main types of EB: simple, junctional and dystrophic, each is caused by mutations in genes that encode epidermal, zones of the basement membrane or dermis proteins, respectively. The fourth type of EB is also described – hemidesmosomal or Kindler syndrome with impairments in kindlin-1 protein encoded by the FERMT1 gene. The existing ways to improve the living conditions of patients with EB are at different stages of development: some of them are already used in the clinic, while others are still under laboratory research. Various strategies are used, depending on the type of EB and the nature of mutation inheritance: from the functional gene replacement therapy based on the viral expression to the genome editing methods by programmable synthetic nucleases. The accumulated experience of allogeneic and autologous transplants of skin equivalents opens the prospect for using new approaches to functional gene and cell therapy ex vivo.
About the Authors
A. K. Beilin
Koltzov Institute of Developmental Biology, Russian Academy of Sciences;
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Vavilova ul. 26, 119334, Moscow
Ostrovitianov ul. 1, 117997, Moscow
N. G. Gurskaya
Koltzov Institute of Developmental Biology, Russian Academy of Sciences;
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Vavilova ul. 26, 119334, Moscow
Ostrovitianov ul. 1, 117997, Moscow
E. A. Vorotelyak
Koltzov Institute of Developmental Biology, Russian Academy of Sciences;
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Vavilova ul. 26, 119334, Moscow
Ostrovitianov ul. 1, 117997, Moscow
References
1. Has C., Bruckner-Tuderman L. The genetics of skin fragility // Annu. Rev. Genomics Hum. Genet. 2014. Vol. 15. P. 245–268.
2. Fine J.D., Eady R.A., Bauer E.A. et al. The classification of inherited epidermolysis bullosa (EB): report of the third international consensus meeting on diagnosis and classification of EB // J. Am. Acad. Dermatol. 2008. Vol. 58. N 6. P. 931–950.
3. Uitto J., Bruckner-Tuderman L., Christiano A.M., McGrath J.A., Has C., South A.P., Kopelan B., Robinson E.C. Progress toward treatment and cure of epidermolysis bullosa: Summary of the DEBRA international research symposium EB2015 // J. Invest. Dermatol. 2016. Vol. 136. N 2. P. 352–358.
4. Lee J.Y.W., Liu L., Hsu C.K., Aristodemou S., Ozoemena L., Ogboli M., Moss C., Martinez A.E., Mellerio J.E., McGrath J.A. Mutations in KLHL24 add to the molecular heterogeneity of epidermolysis bullosa simplex // J. Invest. Dermatol. 2017. Vol. 137. N 6. P. 1378–1380.
5. McGrath J.A. Recently identified forms of epidermolysis bullosa // Ann. Dermatol. 2015. Vol. 27. P. 658–666.
6. Cohn H.I., Teng J.M. Advancement in management of epidermolysis bullosa // Curr. Opin. Pediatr. 2016. Vol. 28. N 4. P. 507–516.
7. Mavilio F., Pellegrini G., Ferrari S., Di Nunzio F., Di Iorio E., Recchia A., Maruggi G., Ferrari G., Provasi E., Bonini C., Capurro S., Conti A., Magnoni C., Giannetti A., De Luca M. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells // Nat. Med. 2006. Vol.12. N 2. P. 1397–1402.
8. Siprashvili Z., Nguyen N.T., Gorell E.S., Loutit K., Khuu P., Furukawa L.K., Lorenz H.P., Leung T.H., Keene D.R., Rieger K.E., Khavari P., Lane A.T., Tang J.Y., Marinkovich M.P. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa // JAMA. 2016. Vol. 316. N 17. P. 1808– 1817.
9. Hirsch T., Rothoeft T., Teig N., et al. Regeneration of the entire human epidermis using transgenic stem cells // Nature. 2017. Vol. 551. N 7680. P. 327–332.
10. Bauer J.W., Koller J., Murauer E.M., De Rosa L., Enzo E., Carulli S., Bondanza S., Recchia A., Muss W., Diem A., Mayr E., Schlager P., Gratz I.K., Pellegrini G., De Luca M. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells // J. Invest. Dermatol. 2017. Vol. 137. N 3. P. 778–781.
11. Sallach J., Di Pasquale G., Larcher F., Niehoff N., Rübsam M., Huber A., Chiorini J., Almarza D., Eming S.A., Ulus H., Nishimura S., Hacker U.T., Hallek M., Niessen C.M., Büning H. Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy // Mol. Ther. 2014. Vol. 22. N 5. P. 929–939.
12. Petek L.M., Fleckman P., Miller D.G. Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex// Mol. Ther. 2010. Vol. 18. N 9. P. 1624–1632.
13. Chamorro C., Mencía A., Almarza D., Duarte B., Büning H., Sallach J., Hausser I., Del Río M., Larcher F., Murillas R. Gene editing for the efficient correction of a recurrent COL7a1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes // Mol. Ther. Nucleic Acids. 2016. Vol. 5:e307.
14. Khan I.F., Hirata R.K., Russell D.W. AAV-mediated gene targeting methods for human cells // Nat. Protoc. 2011. Vol. 6. N 4. P. 482–501.
15. Melo S.P., Lisowski L., Bashkirova E., Zhen H.H., Chu K., Keene D.R., Marinkovich M.P., Kay M.A., Oro A.E. Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant // Mol. Ther. 2014. Vol. 22. N 4. P. 725–733.
16. Gorell E., Nguyen N., Lane A., Siprashvili Z. Gene therapy for skin diseases // Cold Spring Harb. Perspect. Med. 2014. Vol. 4:a015149.
17. March O.P., Reichelt J., Koller U. Gene editing for skin diseases: designer nucleases as tools for gene therapy of skin fragility disorders // Exp. Physiol. 2018. Vol. 103. N 4. P. 449–455.
18. Perdoni C., Osborn M.J., Tolar J. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa // Transl. Res. 2016. Vol. 168. P. 50–58.
19. Aushev M., Koller U., Mussolino C., Cathomen T., Reichelt J. Traceless targeting and isolation of gene-edited immortalized keratinocytes from epidermolysis bullosa simplex patients // Mol. Ther. Methods Clin. Dev. 2017. Vol. 6. P. 112–123.
20. Jinek M., Jiang F., Taylor D.W., Sternberg S.H., Kaya E., Ma E., Anders C., Hauer M., Zhou K., Lin S., Kaplan M., Iavarone A.T., Charpentier E., Nogales E., Doudna J.A. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation // Science. 2014. Vol. 343. N 6176. P. 1247997.
21. Lamb B.M., Mercer A.C., Barbas C.F. 3rd Directed evolution of the TALE N-terminal domain for recognition of all 5’ bases // Nucleic Acids Res. 2013. Vol. 41. N 21. P. 9779–9785.
22. Koo T., Lee J., Kim J.S. Measuring and reducing off-target activities of programmable nucleases including CRISPR-Cas9 // Mol. Cells. 2015. Vol. 38. N 6. P. 475–481.
23. Cui Y., Xu J., Cheng M., Liao X., Peng S. Review of CRISPR/Cas9 sgRNA design tools // Interdiscip. Sci. 2018. Vol. 10. N 2. P. 455–465.
24. Kocher T., Peking P., Klausseger A., Murauer E.M., Hofbauer J.P., Wally V., Lettner T., Hainzl S., Ablinger M., Bauer J.W., Reichelt J., Koller U. Cut and paste: efficient homology- directed repair of a dominant-negative KRT14 mutation via CRISPR/Cas9 nickases // Mol. Ther. 2017. Vol. 25. N 11. P. 2585–2598.
25. Slaymaker I.M., Gao L., Zetsche B., Scott D.A., Yan W.X., Zhang F. Rationally engineered Cas9 nucleases with improved specificity // Science. 2016. Vol. 351. N 6268. P. 84–88.
26. Chen J.S., Dagdas Y.S., Kleinstiver B.P., Welch M.M., Sousa A.A., Harrington L.B., Sternberg S.H., Joung J.K., Yildiz A., Doudna J.A. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy// Nature. 2017. Vol. 550. N 7676. P. 407–410.
27. Osborn M.J., Starker C.G., McElroy A.N. et al. TALEN-based gene correction for epidermolysis bullosa // Mol. Ther. 2013. Vol. 21. P. 1151–1159.
28. Shinkuma S., Guo Z., Christiano A.M. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa // Proc. Natl. Acad. Sci. U.S.A. 2016. Vol. 113. N 20. P. 5676–5681.
29. Saito M., Masunaga T., Teraki Y., Takamori K., Ishiko A. Genotype-phenotype correlations in six Japanese patients with recessive dystrophic epidermolysis bullosa with the recurrent p.Glu2857X mutation // J. Dermatol. Sci. 2008. Vol. 52. N 1. P. 13–20.
30. Webber B.R., Osborn M.J., McElroy A.N., Twaroski K., Lonetree C.L., DeFeo AP, Xia L., Eide C., Lees C.J., McElmurry R.T., Riddle MJ, Kim C.J., Patel D.D., Blazar B.R., Tolar J. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa // NPJ Regen. Med. 2016. Vol. 1:16014.
31. Itoh M., Kiuru M., Cairo M. S., Christiano A.M. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells // Proc. Natl. Acad. Sci. U.S.A. 2011. Vol. 108. P. 8797–8802.
32. Turczynski S., Titeux M., Tonasso L., Décha A., Ishida-Yamamoto A., Hovnanian A. Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model // J. Invest. Dermatol. 2016. Vol. 136. N 12. P. 2387–2395.
33. Koller U., Hainzl S., Kocher T., Hüttner C., Klausegger A., Gruber C., Mayr E., Wally V., Bauer J.W., Murauer E.M. Trans-splicing improvement by the combined application of antisense strategies // Int. J. Mol. Sci. 2015. Vol. 16. N 1. P. 1179–1191.
34. Wally V., Klausegger A., Koller U., Lochmüller H., Krause S., Wiche G., Mitchell L.G., Hintner H., Bauer J.W. 5' trans-splicing repair of the PLEC1 gene // J. Invest Dermatol. 2008. Vol. 128. N 3. P. 568–574.
Review
For citations:
Beilin A.K., Gurskaya N.G., Vorotelyak E.A. METHODS OF GENE THERAPY FOR TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA. Vestnik Moskovskogo universiteta. Seriya 16. Biologiya. 2018;73(4):233-241. (In Russ.)
Views:
622
Email this article 